PHASQ stock down 99% to $0.000001 on PNK 09 Jan 2026: what traders should watch
PHASQ stock plunged -99.0% to USD 0.000001 on the PNK exchange during market hours on 09 Jan 2026. We saw volume of 2,500 shares against a 50-day average of 22,310. The move follows a history of Chapter 11 restructuring and continued clinical-stage risk for PhaseBio Pharmaceuticals, Inc. The price collapse reflects near-zero market cap, thin liquidity, and persistent development uncertainty for bentracimab and other pipeline assets
PHASQ stock: market move and intraday metrics
PHASQ stock fell from a previous close of USD 0.000100 to USD 0.000001 on 09 Jan 2026. The session range was USD 0.000001 to USD 0.000001 with reported volume 2,500. This drop registers as a -99.0% one-day change and places the stock at its year low of USD 0.000001.
Traders should note the liquidity risk. Average volume is 22,310, so a small trade can swing the price. The stock’s 50-day average is USD 0.000236 and 200-day average is USD 0.000666, underscoring the sustained downtrend.
PHASQ stock: financials and key ratios
PhaseBio reports EPS of -2.14 and a negative PE. The company shows revenue per share TTM of 0.000368 and negative net income per share of -0.004459. Cash per share is 1.421879, while book value per share is -3.164667, indicating balance sheet stress.
Key ratios reveal a current ratio of 1.75 and interest coverage of 137.72, but enterprise value figures are distorted at -33,955,000.00. These mixed metrics reflect a clinical-stage biotech with meaningful operating losses and episodic cash positions.
PHASQ stock: clinical pipeline and news drivers
PhaseBio’s lead candidate is bentracimab (PB2452), a ticagrelor reversal agent now in Phase III. The company also develops PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension. Historical news includes a Chapter 11 filing on 23 Oct 2022.
Clinical readouts, regulatory decisions, or partner milestones will remain the primary value drivers. Absent positive data or new funding, the market is pricing acute downside and very high binary risk for PHASQ stock.
PHASQ stock: technicals and trading risks
Technically, PHASQ shows extreme volatility and severe price decay. The stock has a year high of USD 0.039900 and a year low of USD 0.000001, a collapse of over 99.99% year to date. Price averages and low float create steep slippage risks for any sized order.
Short-term traders face execution risk and wide effective spreads. Long-term investors face dilution and binary clinical events that could render shares effectively worthless.
Meyka AI rates PHASQ with a score out of 100 and valuation view
Meyka AI rates PHASQ with a score out of 100: 63.07 | Grade B | Suggestion: HOLD. This grade factors S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst consensus. These grades are informational only and not financial advice.
Meyka AI’s forecast model projects USD 0.000100 as a base-case 12-month scenario. Versus current USD 0.000001, that implies an upside of approximately 9,900.00%. We present scenario targets: Bear USD 0.000001, Base USD 0.000050, Bull USD 0.000100. Forecasts are model-based projections and not guarantees.
PHASQ stock: buy, hold, or sell considerations
Investors should treat PHASQ stock as a high-risk speculative position. Catalysts include Phase III bentracimab results, new financing, or partnership deals. Absent catalysts, downside risk is material and liquidity remains minimal.
Position sizing and stop rules matter. For diversified portfolios, PHASQ is suitable only for traders who accept total-loss risk and can tolerate extreme volatility.
Final Thoughts
PHASQ stock closed the session at USD 0.000001 on 09 Jan 2026 after a -99.0% intraday fall. The move highlights acute liquidity stress, clinical-stage binary risk, and balance sheet strain despite pockets of cash per share. Our Meyka AI grade of 63.07 (B, HOLD) reflects mixed signals: pipeline value exists, but market pricing already assumes severe downside.
Meyka AI’s forecast model projects a base-case USD 0.000100 within 12 months, implying roughly 9,900.00% upside versus USD 0.000001 today. That scenario requires successful clinical or financing catalysts. Traders should weigh tiny free-float dynamics and consider tight risk controls. For active traders we recommend monitoring clinical timelines and liquidity levels. For longer-term holders, prioritize verified financing or partnering news before adding exposure. Sources: PhaseBio website and PhaseBio Twitter. Meyka AI provided this AI-powered market analysis
FAQs
Why did PHASQ stock drop 99% on 09 Jan 2026?
PHASQ stock fell due to thin liquidity, Chapter 11 history, and ongoing clinical and financing uncertainty. Low volume of 2,500 shares amplified the move. Market participants priced in severe downside absent near-term positive catalysts.
What are the main financial metrics for PHASQ stock?
Key metrics: EPS -2.14, revenue per share TTM 0.000368, cash per share 1.421879, price averages 50/200 days 0.000236/0.000666, and current price USD 0.000001. These show operating losses with intermittent cash cushions.
What does Meyka AI forecast for PHASQ stock?
Meyka AI’s forecast model projects a base-case of USD 0.000100 in 12 months. Versus current USD 0.000001, that implies roughly 9,900.00% upside. Forecasts are model-based projections and not guarantees.
Should investors buy PHASQ stock now?
PHASQ stock is speculative and high risk. Consider it only for tiny, well-sized positions. Wait for clinical readouts, firm financing, or partnership updates before increasing exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
